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Platelet Disorders
Introduction
The gray platelet syndrome (GPS, OMIM #139090) is a rare
inherited bleeding disorder characterized by macrothrombo-
cytopenia and reduction of α-granules in platelets and in
megakaryocytes.1 Alpha-granules are the most abundant
granules in platelets and store proteins that promote platelet
adhesiveness, blood coagulation and wound healing when
secreted during platelet activation. Some α-granule proteins
are synthesized in megakaryocytes and packed into these
vesicles, whereas others are either passively or actively taken
up from the plasma by receptor-mediated endocytosis.2,3
Their defective maturation causes a continuous leakage of
growth factors and cytokines into the bone marrow, which
leads to the development of myelofibrosis.2-4
Genome-wide linkage analysis mapped the GPS locus on
chromosome 3p21.5,6 More recently, three independent next
generation approaches identified NBEAL2 as the gene respon-
sible for GPS.1,7,8 NBEAL2 encodes a 2,754 amino acid
polypeptide, neurobeachin-like-2, similar to the lysosomal
trafficking regulator (LYST). Interestingly, LYST is responsible
for Chediak-Higashi syndrome (CHS) which is characterized
by deficiency of platelet δ-granules and abnormalities of
other cells.9 Like LYST, NBEAL2 contains the BEACH (beige
and CHS), ARM (Armadillo) and WD40 domains, highly con-
served regions that are crucial for protein-protein interac-
tions, membrane dynamics and vesicle trafficking.10
In this article, we describe 11 probands with large platelets
and α-granule reduction, and therefore with a diagnostic sus-
picion of GPS. The search for mutations in NBEAL2 allowed
us to confirm the diagnosis in four families. The clinical and
laboratory characteristics observed in biallelic patients and
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The gray platelet syndrome is a rare inherited bleeding disorder characterized by macrothrombocytopenia and defi-
ciency of alpha (α)-granules in platelets. The genetic defect responsible for gray platelet syndrome was recently
identified in biallelic mutations in the NBEAL2 gene. We studied 11 consecutive families with inherited
macrothrombocytopenia of unknown origin and α-granule deficiency. All of them underwent NBEAL2 DNA
sequencing and evaluation of the platelet phenotype, including a systematic assessment of the α-granule content by
immunofluorescence analysis for α-granule secretory proteins. We identified 9 novel mutations hitting the two alle-
les of NBEAL2 in 4 probands. They included missense, nonsense and frameshift mutations, as well as nucleotide
substitutions that altered the splicing mechanisms as determined at the RNA level. All the individuals with NBEAL2
biallelic mutations showed almost complete absence of platelet α-granules. Interestingly, the 13 individuals
assumed to be asymptomatic because carriers of a mutated allele had platelet macrocytosis and significant reduction
of the α-granule content. However, they were not thrombocytopenic. In the remaining 7 probands, we did not iden-
tify any NBEAL2 alterations, suggesting that other genetic defect(s) are responsible for their platelet phenotype. Of
note, these patients were characterized by a lower severity of the α-granule deficiency than individuals with two
NBEAL2 mutated alleles. Our data extend the spectrum of mutations responsible for gray platelet syndrome and
demonstrate that macrothrombocytopenia with α-granule deficiency is a genetic heterogeneous trait. In terms of
practical applications, the screening of NBEAL2 is worthwhile only in patients with macrothrombocytopenia and
severe reduction of the α-granules. Finally, individuals carrying one NBEAL2 mutated allele have mild laboratory
abnormalities, suggesting that even haploinsufficiency has an effect on platelet phenotype.
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ABSTRACT
their monoallelic family members, as well as those of the
remaining 7 families without NBEAL2 mutations, better
define the picture of GPS. The data also help to improve
the criteria for differential diagnosis of inherited
macrothrombocytopenias with α-granule deficiency.
Design and Methods
Patients
We studied 11 consecutive unrelated probands with congenital
macrothrombocytopenia associated with deficiency of α-granules
on evaluation of peripheral blood smears. All the subjects or their
legal guardians gave written informed consent according to the
Declaration of Helsinki. Protocols were approved by the Ethics
Review Boards at the institutions that enrolled the patients. On
examination of May-Grünwald-Giemsa (MGG)-stained slides, all
the patients had a remarkable, although variable, percentage of
platelets (approx. 30%-95%) with no or very few azurophilic
granules, and therefore presenting a gray appearance.11 A clinical
and cytopathological diagnosis of GPS was made in 6 of these
probands (Families 1-5 and 11), 4 of which (Families 1, 3, 4, and 5)
had been previously reported.12-14 All the patients underwent
immunofluorescence analysis of α-granule secretory proteins and
DNA sequencing of NBEAL2 (see below). Their clinical and labora-
tory findings are reported in more detail in the Online
Supplementary Appendix and Online Supplementary Tables S1-S3.
Immunofluorescence analysis of platelet α-granule
content 
We quantified the platelet α-granule content by immunofluo-
rescence labeling for the α-granule proteins thrombospondin-1
(TSP1) and platelet factor 4 (PF4), according to a previously pub-
lished method.12,15 Blood slides were prepared without anticoagu-
lant by prick of the fingertip and immediately air-dried. Slides
were then fixed in 4% paraformaldehyde in phosphate buffered
saline (PBS) for 20 min at room temperature (RT), washed with
PBS, and permeabilized with 0.1% Triton-X-100 (Sigma, St. Louis,
MO, USA) in PBS for 5 min. After washing with PBS, slides were
incubated with the P12 antibody anti-TSP1 (Sigma) or a rabbit
anti-PF4 (Chemicon, Temecula, CA, USA) for 1 h at RT. The
appropriate goat Alexa Fluor 594-conjugated anti-mouse or anti-
rabbit was used as secondary antibody (Invitrogen, Carlsbad, CA,
USA). In all the cases, the TSP1 and PF4 reactions resulted to be in
a well-defined granular staining pattern; in normal platelets, a large
number of granules were aggregated in the structure of granulom-
ere, while in defective platelets the single TSP1- or PF4-positive
granules could be identified and counted. For each subject, we cal-
culated the percentage of platelets with less or more than 5 TSP1
or PF4-positive granules, as previously reported.12,15 The cut off of
5 granules was fixed empirically to categorize exclusively those
platelets who presented a very marked reduction in TSP1-positive
or PF4-positive granules. At least 300 platelets were observed and
classified for each specimen. Results obtained in patients were
compared with those obtained in 20 consecutive healthy subjects
that were stained in parallel, as well as with those deriving from a
series of 50 healthy subjects analyzed previously.12 Analysis of
cases and controls was performed blind.
Transmission electron microscopy
A systematic morphometric analysis of the granule content of
platelets was performed in the proband of Family 1 and in his 2
relatives carrying one mutated NBEAL2 allele by electron
microscopy. Fifteen consecutive healthy controls were also includ-
ed in the study. Platelets were immediately fixed with 1.25% glu-
taraldehyde in White’s buffer saline prior to obtaining platelet-rich
plasma, and post-fixed with 1% osmium tetroxide. The samples
were dehydrated in alcohol and embedded in Epon 812 (Electron
Microscopy Sciences, Hatfield, PA, USA). Ultrathin sections were
stained using standard solutions of uranyl acetate and lead citrate,
and examined by transmission electron microscopy at 80 Kv accel-
erating voltage.16 For each specimen, random microscopic fields
were taken and at least 100 platelet sections were analyzed. The
granule content was expressed as the mean number of granules
per unit of platelet section (m2).
Evaluation of mean platelet diameter
Mean platelet diameters were assessed on MGG-stained blood
smear by software assisted image analysis (Axiovision 4.5, Carl
Zeiss, Göttingen, Germany) as previously described.17
DNA sequencing 
NBEAL2 was screened for mutations using genomic DNA
extracted from peripheral blood. Mutational analysis was per-
formed by polymerase chain reaction (PCR) amplification using
primers (available upon request) covering exons and the
exon/intron boundaries of the gene. PCR was carried out in 35 mL
of total reaction volume with 25 ng of genomic DNA, 10 mM of
each primer, and Kapa 2G Fast Hot Start ReadyMix 2X
(KapaBiosystems, Cape Town, South Africa). After initial denatu-
ration at 95°C for 1 min, amplification was performed for 30
cycles (denaturation at 95°C for 10 s, annealing at 62°C for 10 s,
and elongation at 72°C for 1 s). PCR products were bidirectionally
sequenced using the ABI PRISM BigDye v3.1 Terminator Cycle
Sequencing Ready Reaction Kit and ABI PRISM 3130xl sequencer
(Applied Biosystems, Foster City, CA, USA).
Real-time polymerase chain reaction 
Total RNA was extracted from patient's derived lymphoblas-
toid cell lines or peripheral blood using TRIzol® (Life
Technologies, Carlsbad CA, USA) and cDNA was synthesized
with Transcriptor First Strand cDNA Synthesis Kit (Roche Applied
Science, Foster City, CA, USA). In the probands of Families 1 and
2, the amplification reactions were performed using the following
pairs of primers: 33F (5'-GCGCCGAGACATATTCACGC-3') -
37R (5'-AAGAGCTCAAGTGCTGAACG-3'), and 41F (5'-GAT-
GTGAAGGAGCTCATCCC-3') - 43R (5'-AGAAGA-
CATTGAGGGCCTCC-3'), respectively. RT-PCR was carried out
for 30 cycles, 40 s at 95°C, 45 s at 60°C and 45 s at 72°C.
Bioinformatic analysis
The effect of the missense variations on protein function was
evaluated using a variety of patogenicity prediction programs,
such as PoliPhen-2 (POLYmorphism PHENOtyping 2, http://genet-
ics.bwh.harvard.edu/pph2/), MutationAssessor (http://mutationasses-
sor.org/) and MutationTaster (http://www.mutationtaster.org/).
Regarding splice-site mutations, in silico analyses were carried out
using Splice Site Prediction by Neural Network (NNSplice;
http://www.fruitfly.org/seq_tools/splice.html) and Human Splicing
Finder Version 2.4.1 (http://www.umd.be/HSF/).
Results
Identification of NBEAL2 mutations in four families
Direct sequencing of the NBEAL2 gene revealed 9 differ-
ent novel mutations in the probands of Families 1-4 (Table
1). The identified alterations were not reported in the
dbSNP database (http://www.ncbi.nlm.nih.gov/snp/).
Molecular genetic analysis of the proband of Family 1
detected a paternal deletion of 4 nucleotides
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(c.1504_1507del) in exon 13, which produces a frameshift
and a premature stop codon 4 amino acids downstream of
the mutation (Figure 1C). The second mutation, a
nucleotide substitution (c.6801+7A>T) in intron 42, was
inherited from the mother and was expected to generate a
donor splice-site (GAGgtgag) stronger than the natural site
(CTGgtgag). In fact, the splicing prediction tool NNSplice
attributed scores 0.83 and 0.75 to the mutated and the nat-
ural splice-site, respectively (Figure 1D).
The proband of Family 2 (II-1) carried three mutations,
a maternal missense mutation (c.7033C>T, p.Arg2345Trp)
in exon 45 and two paternal nonsense mutations:
c.5572C>T (p.Arg1858*) and c.6652G>T (p.Glu2218*). His
brother inherited the paternal mutated allele.
Consistent with their parents’ consanguinity, the 2
affected brothers of Family 3 were homozygous for a non-
sense mutation (c.2187C>A) that is expected to truncate
the protein at amino acid 728. 
Finally, we identified three different mutations in Family
4: a nucleotide deletion in exon 12 (c.1253del) that intro-
duces an in-frame premature stop codon
(p.His418Leufs*54), a splice variant (c.5720+1G>A) in
intron 35, and a missense mutation, c.3584G>A
(p.1195Arg>Gln) (Figure 2). The c.1253delA deletion was
a maternal mutation while the other two mutations were
inherited from the father. The paternal allele was also
detected in individuals II-4, III-5 and IV-3 but not in the
other family members (II-2 and in his descendants) though
they had partial reduction of α-granules. The disruption of
the natural donor splice-site by the c.5720+1G>A muta-
tion was expected to lead to recognition of putative cryp-
tic sites. In fact, NNSplice prediction recognized three “gt”
splice sites located at nucleotide positions 30 (score 83), 35
(score 81) and 149 nt  (score 93) of intron 35.
Splicing mutations lead to frameshift alterations
To test the effect of the two splicing variants, we per-
formed RT-PCR using total RNA extracted from peripheral
blood (Family 1) or lymphoblastoid cell line (Family 4). As
predicted by the bioinformatics tools, in Family 1 reverse-
transcriptase polymerase chain reaction (RT-PCR) and
sequencing analysis confirmed that the amplified product
consisted of both wild-type and mutated alleles (Figure 1D
and Table 1). The latter was characterized by an alterna-
tive splicing due to an out of frame insertion of the first 5
nucleotides of intron 42 (p.Glu2268Valfs*44). In the pres-
ence of the c.5720+1G>A mutation (Family 4), the splicing
machinery recognized the cryptic site with the highest
score. Indeed, the analysis revealed products characterized
by the insertion of 148 nucleotides (r.5720_5721ins148) of
intron 35 (Figure 2C and Table 1). The first inserted codon
is a stop codon leading to a premature truncated product
(p.Met1908*).
Potential pathogenetic effect of missense mutations
Missense mutations were identified in Families 2 and 4
(Table 1). The potential effect of the two missense muta-
tions on protein function was evaluated using different
pathogenicity prediction programs. Regarding
p.1195Arg>Gln, the significance of this variant is unclear
because of its low pathogenicity scores (PoliPhen-2, score
0.398; MutationTaster, polymorphism P=0.995;
MutationAssessor, FI score 1.04). However, this alteration
is likely not to exert any effect because localized in cis of
p.Met1908*.
On the other hand, the p.Arg2345Trp variant is likely to
be pathogenetic because of its high prediction scores
(PolyPhen2, score 1; MutationTaster, disease-causing
mutation P=0.997; MutationAssessor, FI score 3.55). It
alters a highly conserved amino acid of the BEACH bind-
ing domain. However, since it is the only mutation carried
by the maternal allele in Family 2, only functional studies
would be able to confirm the hypothesis.
Platelet features of patients with biallelic mutations of
NBEAL2
All the 5 subjects with biallelic NBEAL2 mutations had
thrombocytopenia (Table 2 and Online Supplementary Table
S1). On examination of MGG-stained blood smears, all of
them had platelet macrocytosis and giant platelets; the
mean platelet diameter was 3.9 mm (P<0.001 with respect
to healthy subjects) (Table 2). Immunofluorescence analy-
sis for TSP1 showed a severe reduction of platelet α-gran-
ule content in all the patients, as the percentage of
platelets with more than 5 TSP1 positive granules ranged
from 3% to 12% (P<0.0001 compared to healthy subjects)
(Figure 3 and Table 2). The PF4 content evaluation gave
similar values (data not shown). These data were consistent
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Table 1. Mutations in NBEAL2 identified in four unrelated families.
Family cDNAa Exon/Intron Protein Type of mutation Transmission
(RNA for splicing mutations)
13 c.1504_1507del 13 p.Leu502Alafs*4 Frameshift Paternal
c.6801+7A>T
(r.6801_6802insGTGAG) i42 p.Glu2268Valfs*44 Splice-site Maternal
Frameshift
c.5572C>T 34 p.Arg1858* Nonsense Paternal
2 c.6652G>T 41 p.Glu2218* Nonsense Paternal
c.7033C>T 45 p.Arg2345Trp Missense Maternal
314 c.2187C>A 16 p.Tyr729* Nonsense Maternal 
and paternal
412 c.1253del 12 p.His418Leufs*54 Frameshift Maternal
c.3584G>A 25 p.Arg1195AGln Missense Paternal
c.5720+1G>A i35 p.Met1908* Splice-site Paternal
(r.5720_5721ins148) Frameshift
aNucleotide A of the ATG translation initiation start site of the NBEAL2 cDNA in GenBank sequence NM_015175.1 is indicated as nucleotide +1.
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Figure 2. Mutation analysis of NBEAL2 in Family 4. (A) Pedigree of the family showing genotypes of 10 individuals. The proband IV-4 is indi-
cated by a black symbol while the other individuals with α-granule deficiency and/or thrombocytopenia are in gray symbols. The proband
carries three mutations: a maternal frame-shifting deletion (c.1253del) and two paternal (c.3584G>A and c.5720+1G>A) mutations. (B)
Chromatogram of the heterozygous splice-site c.5720+1G>A mutation in the proband. (C) RT-PCR analysis of the proband’s RNA extracted
from his lymphoblastoid cell line. As confirmed by direct sequencing, the mutation causes an alternative splicing of a 629 bp product instead
of the wild-type 481 bp fragment due to the recognition of a cryptic splicing donor site 148 nucleotide downstream of the natural one.
Figure 1. Mutation analysis of NBEAL2 in Family 1. (A) Pedigree of Family 1 with segregation of mutations. (B) Electron microscopy of
platelets from proband II-1, showing a severe reduction of α-granules. A few very small  α-granules are visible. Dense bodies are normal in
number and morphology (bar = 1 mm). (C) Chromatograms of PCR product of exon 13 showing an heterozygous 4-bp frame-shifting deletion
c.1504_1507del. (D) Sequence analysis of the RT-PCR product showing the alternative splicing r.6801_6802insGTGAG due to the
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with those from electron microscopy, showing severe
reduction platelet α-granules in the proband of Family 1
(Figure 1B and Table 3). Specifically, the mean α-granule
number per unit of platelet area was 10% with respect to
controls. Instead, the content of δ-granules was in the nor-
mal range (Table 3). Similarly, a severe reduction of α-
granules was reported for the proband of Family 4.12
Platelet features of NBEAL2 monoallelic individuals
None of the 13 relatives with one mutated NBEAL2
allele had thrombocytopenia, suggesting a recessive trans-
mission of this trait (Table 2). However, 9 individuals had
evident platelet macrocytosis, while the other 4 had mean
platelet diameter near to the upper limit of the normal
range. Considering all the NBEAL2 monoallelic individu-
als, their mean platelet diameter was significantly
increased with respect to controls (3.1 vs. 2.4; P<0.001)
(Table 2).
Moreover, a careful examination of their MGG-stained
slides demonstrated that most of these patients presented
with some distinct gray platelets. Consistently, immuno-
fluorescence analysis showed that all but one (III-8 of
Family 4 who had 90% of platelets with >5 TSP1 positive
granule) had moderate reduction in the α-granule content.
The mean percentage of platelets with more than 5 TSP1
positive granules was 71% and it was significantly
reduced with respect to healthy controls (P<0.0001) but
higher than that observed in NBEAL2 biallelic individuals
(P<0.0001) (Figure 3 and Table 2). The statistical signifi-
cance (P<0.0001) was maintained even excluding the 4
carriers from Family 4, where the partial α-granule defect
did not completely segregate with the NBEAL2mutations.
In order to confirm the partial α-granule deficiency
observed by immunofluorescence analysis, we carried out
electron microscopy in the two NBEAL2 carriers belonging
to family 1 (Table 3). While the δ-granule content was nor-
mal, that of the α-granules was partially reduced in both
subjects. In more details, the mean α-granule number per
unit of platelet area was 71% and 61%, of controls in the
father (I-1) and the mother (I-2), respectively (Table 3). The
electron microscopy also confirmed the platelet macrocy-
tosis in these 2 individuals.
Finally, none of the NBEAL2 carriers had other clinical or
laboratory signs of GPS (Online Supplementary Table S2). 
Platelet features in individuals with thrombocytopenia
and no NBEAL2 mutations
Direct sequencing of NBEAL2 did not identify any muta-
tions in the probands of the remaining Families 5-11,
though two of them had been previously diagnosed as
GPS.12-14 In these subjects, macrothrombocytopenia and α-
granule deficiency was sporadic or inherited as an autoso-
mal dominant trait (Online Supplementary Table S3). All these
patients had moderate to severe thrombocytopenia and
most of them had increased MPV. The mean values of their
platelet count and volume did not differ from those of the
patients with biallelic mutations. However, their α-granule
Table 2. Platelet phenotypes (quantification of α-granule defect, platelet
macrocytosis and platelet count) in relation to the NBEAL2 genotypes.
NBEAL2 genotype Alpha-granule defect Mean platelet Platelet count
(N. of individuals) (% of platelets with diameter (mm) (x109/L)
>5 TSP1 positive granules) Mean [range] Mean [range]
Mean [range]
-  / -  (5)a 7  [3-12]e,f 3.9 [3.5-4.3]g,h 58 [30-85]
+ / -  (13)b 71 [57-90]e 3.1 [2.5-4.0]g 233 [170-320]
+ / +  (7)c 60 [37-69]e 3.9 [3.3-4.8]g 62 [38-110]
Controls (20)d 95 [92-99] 2.4 [2.0-2.7] 245 [180-347]
aIndividuals from Families 1-4 with NBEAL2 biallelic mutations. bIndividuals from Families 1-4
with NBEAL2 monoallelic mutations. cProbands of Families 5-11 (macrothrombocytopenia and α-
granule deficiency but no NBEAL2 alterations). dHealthy subject whose smears were studied in
parallel with the analyzed patients. In a previous series of 50 healthy subjects the median propor-
tion of platelets with >5 granules was 96.2% (range 94.2-98.0) eP<0.0001 with respect to healthy
controls (two-tailed Student’s t test). fP<0.0001 with respect to individuals with NBEAL2 geno-
types  +/-  and  +/+. gP<0.001 with respect to healthy controls. hP<0.01 with respect to individuals
with NBEAL2 genotype +/-. 
Figure 3. Immunofluorescence analysis for platelet TSP1 in the
members of Family 2. Platelets were identified on the blood smear
by labeling for F-actin (green), while TSP1 was analyzed in the red
channel. (II-1): the proband with biallelic NBEAL2 mutation. Marked
platelet macrocytosis with giant platelets and almost complete
absence of TSP1 positive granules; the insert shows a giant platelet
with a single TSP1 positive granule. (I-1 and I-2 ): father (I-1) and
mother (I-2) of the proband with monoallelic NBEAL2 mutations.
Representative fields of the finding of platelets with normal TSP1
positive granule content (very large number of TSP1+ granules
packed in the structure of granulomere) together with platelets with
no granules at all or with marked reduction of TSP1 positive gran-
ules (< 5 granules). Both monoallelic individuals also presented
moderate platelet macrocytosis, which was more evident in the
mother (H). In (H) platelets from a healthy control are shown for
comparison. Scale bars correspond to 10 microns.
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reduction was significantly less severe than that of individ-
uals with NBEAL2 biallelic mutations (P<0.0001) (Table 2).
Discussion
After the recent identification of mutations of NBEAL2
in patients with GPS, we hypothesized that this gene was
responsible for low platelet count and α-granule deficien-
cy in 11 unrelated probands with inherited thrombocy-
topenia. The analysis allowed us to identify mutations hit-
ting both NBEAL2 alleles in four families. The 5 affected
individuals from these pedigrees had a very marked reduc-
tion in the α-granule content (88%-97% of platelets
devoid of α-granules) which was associated with platelet
macrocytosis and giant platelets. These features are simi-
lar to those of the patients with NBEAL2 biallelic muta-
tions identified so far.1,7,8
Moreover, we observed for the first time that the
monoallelic family members had laboratory abnormali-
ties, such as a moderate reduction in the α-granule content
and platelet macrocytosis. These results confirm previous
observations of moderate laboratory signs in obligate car-
riers.12 These modest anomalies are likely to have no clin-
ical relevance in many cases, since only one monoallelic
individual (III-7 of Family 4) had prolonged bleeding time
and mild bleeding diathesis with platelet counts at the
lower limit (170 x 109/L) of the normal range.12 Even if an
extensive clinical and laboratory characterization could
rule out alternative causes of the bleeding diathesis,
whether the NBEAL2 mutated allele or other unrecog-
nized factors are responsible for the bleeding tendency of
this subject is currently unknown.
The finding of platelet abnormalities in the NBEAL2 car-
riers was unexpected, particularly for what concerns the
α-granule phenotypes. At first, the estimation was carried
out by immunofluorescence analysis, which, although
conducted with a standardized approach,12,18 is not a vali-
dated procedure to study α-granule deficiency. Thus, we
measured the α-granule number per unit of platelet area
by electron microscopy in the 2 carriers (Family 1) whose
biological samples were available for the analysis. The
evaluation was carried out in parallel with the proband of
the same family. The analysis confirmed not only the
severe reduction of platelet α-granules in the proband but
also the mild α-granule defect in the 2 NBEAL2 carriers.
Interestingly, similar degrees of deficiency were measured
by electron microscopy and immunofluorescence in the
same individual. Although the immunofluorescence pro-
tocol has to be validated in a large number of samples, the
two methodologies provided similar results in quantifying
the extent of α-granule deficiency. 
Since mutations affecting only one NBEAL2 allele were
associated with platelet abnormalities, we hypothesized
that mutations in this gene could be responsible for autoso-
mal dominant thrombocytopenia with α-granule deficien-
cy. However, the analysis of another 7 probands (including
autosomal dominant and sporadic forms) with congenital
thrombocytopenia and α-granule defect did not identify
any NBEAL2mutations. Since the other inherited thrombo-
cytopenias characterized by α-granule deficiency, such as
those caused by mutations of ANKRD26 or GATA1, were
excluded, we conclude that one or more unknown genes
are responsible for the congenital defects in these cases. Of
note, the probands without NBEAL2 mutations had lower
severity of the α-granule deficiency (31%-63% of platelets
devoid of granules) compared to those with biallelic muta-
tions (P<0.0001). Based on these findings, it is reasonable to
assume that the α-granule deficiency is a genetic heteroge-
neous trait with variable expressivity and that the diagnosis
of GPS associated with mutations of NBEAL2 has to be sus-
pected only in subjects with macrothrombocytopenia and
at least 85% of platelets devoid of α-granules.
Therefore, the comparison of the phenotypes of sub-
jects with NBEAL2 monoallelic and biallelic mutations
suggests a dosage effect. In carriers, haploinsufficiency of
NBEAL2 affects the size and the α-granule content of
platelets. In addition to these platelet defects, loss of func-
tion due to biallelic mutations of NBEAL2 leads to throm-
bocytopenia. These results helps our understanding of the
effect of NBEAL2 mutations on platelet dysfunction/bio-
genesis.
DNA sequencing of NBEAL2 allowed us to identify 9
novel alterations of the gene, including 2 missense, 3 non-
sense, 2 frameshift, as well as 2 splicing alterations con-
firmed at the RNA level. Together with those previously
reported, they increase to 35 the number of different
mutations identified in 27 GPS unrelated families.1,7,8
Although NBEAL2 encodes a protein of 2,754 amino acids
characterized by specific domains, mutations are spread
throughout the entire gene without evidence for any
founder effect, as 31 out of 35 of the mutations are private.
Moreover, despite the rarity of the disease, 10 out of 27
probands are compound heterozygous, suggesting that
the disease might be more frequent than expected.
The role of NBEAL2 is unknown, as well as the patho-
genetic mechanisms responsible for α-granule deficiency,
macrothrombocytopenia and the other features of the dis-
ease. Investigations focused on understanding these
aspects, as well as studies on large series of cases, will be
of fundamental importance to improve our knowledge of
this disease. 
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Table 3. Platelet features determined by electron microscopy in mem-
bers of family 1 (see Figure 1).
Platelet features I-1 I-2 II-1 Healthy controls
(Father) (Mother) (Proband) (n=15), mean 
[range]
Section areaa 2.5 2.6 2.7 1.6 [1.5-2.0]
α-granulesb 2.2 1.9 0.3 3.1 [2.8-3.3]
δ-granulesb 0.3 0.2 0.3 0.3 [0.2-0.4]
aMean area of platelet sections measured in m2. bGranule content was expressed as the
mean number of granules per unit (µ2) of platelet section.
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